Geneuro Logo

Geneuro

GEM | PA

Overview

Corporate Details

ISIN(s):
CH0308403085
LEI:
213800FUJCKXO9LK3444
Country:
Switzerland
Address:
chemin du Pré-Fleuri 3, 1228 Plan-les-Ouates
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

GeNeuro is a Swiss-based, clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative and autoimmune diseases. The company utilizes a novel therapeutic approach that targets pathogenic proteins encoded by human endogenous retroviruses (HERVs), which are believed to contribute to the progression of diseases such as Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), and post-COVID conditions. Its main drug candidate, temelimab, is being developed to treat the cognitive and fatigue symptoms associated with Long COVID. In July 2024, the company was granted a debt-restructuring moratorium.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Geneuro. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-30 19:37
Post-Annual General Meeting Information
Inside Information / Other news releases
English 224.5 KB
2025-06-30 19:37
Post-Annual General Meeting Information
Informations privilégiées / Autres communiqués
French 753.1 KB
2025-06-12 22:42
Legal Proceedings Report
Inside Information / Other news releases
English 204.9 KB
2025-06-12 22:42
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 203.8 KB
2025-06-10 18:24
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 207.4 KB
2025-06-10 18:24
Pre-Annual General Meeting Information
Inside Information / Other news releases
English 209.5 KB
2025-05-27 18:00
Legal Proceedings Report
Inside Information / Other news releases
English 162.5 KB
2025-05-27 18:00
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 187.1 KB
2025-05-12 18:36
Report Publication Announcement
Inside Information / Other news releases
English 481.8 KB
2025-05-12 18:36
Report Publication Announcement
Informations privilégiées / Autres communiqués
French 669.5 KB

Automate Your Workflow. Get a real-time feed of all Geneuro filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Geneuro via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Circio Holding ASA Logo
Developing circular RNA medicines for gene and cell therapies for hard-to-treat diseases.
Norway CRNA
CIZZLE BIOTECHNOLOGY HOLDINGS PLC Logo
Developing a blood test for early lung cancer detection using a proprietary CIZ1B biomarker.
United Kingdom CIZ
Combigene AB Logo Sweden COMBI
Compugen Ltd. Logo
AI-driven discovery of novel antibody therapies for cancer immunotherapy.
Israel CGEN
Virgin Islands (British) N/A
Cte Group Spolka Akcyjna Logo
Provides B2B services, corporate events, and advanced composite materials R&D.
Poland LPS
Curasight A/S Logo
Developing a theranostics platform for precise diagnosis and targeted radiation therapy for cancer.
Denmark CURAS
Cyclezyme AB Logo
Develops enzymes to recycle PET plastic waste into new high-quality materials.
Sweden CYCLE
Cyxone AB Logo Sweden CYXO
DARWIN AG Logo
AI-powered biotech creating personalized health solutions from biological data for B2C & B2B.
Germany 7V0